Anthony Hunter MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Emory University School of Medicine, Winship Cancer Institute

1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900

Dr. Hunter is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hunter's full profile Already have an account?

Summary

Dr. Anthony Hunter is a hematologist based in Atlanta, GA, specializing in hematologic oncology and myeloproliferative disorders. He completed his fellowship in hematology and medical oncology at the University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital and his residency in internal medicine at Emory University School of Medicine. He graduated from the Medical College of Wisconsin in 2014. Dr. Hunter has been serving as an assistant professor at Emory University School of Medicine since 2020, following his clinical fellowship at the H. Lee Moffitt Cancer Center and Research Institute. With experience in leukemia, his recent publications include studies on chronic myeloid leukemia and polycythemia vera, with research featured in journals such as Hematology, Blood Neoplasia, Current Hematologic Malignancy Reports, Annals of Hematology, and Supportive Care in Cancer.

Education & Training

University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2017 - 2020
Emory University School of MedicineResidency, Internal Medicine, 2014 - 2017
Medical College of WisconsinClass of 2014

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

GA State Medical License 2020 - 2027
FL State Medical License 2017 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EX...
Brandi N Reeves, Firas El Chaer, Lynda Foltz, Tsewang Tashi, Ghaith Abu-Zeinah
Lancet Regional Health. Americas. 2026-09-01
Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.
Anthony Michael Hunter, Albert Qin, Lucia Masarova, Ghaith Abu-Zeinah, Sung-Eun Lee
Leukemia & Lymphoma. 2026-07-17
1 citations
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
Luca Lanino, Anthony M Hunter, Nico Gagelmann, Marie Robin, Daniele Dall'Olio
Journal of Clinical Oncology. 2026-06-10

Abstracts/Posters

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Anthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
Anthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019